1. Home
  2. SAVA vs MCHX Comparison

SAVA vs MCHX Comparison

Compare SAVA & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAVA
  • MCHX
  • Stock Information
  • Founded
  • SAVA 1998
  • MCHX 2003
  • Country
  • SAVA United States
  • MCHX United States
  • Employees
  • SAVA N/A
  • MCHX N/A
  • Industry
  • SAVA Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • SAVA Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • SAVA Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • SAVA 102.4M
  • MCHX 84.3M
  • IPO Year
  • SAVA N/A
  • MCHX 2004
  • Fundamental
  • Price
  • SAVA $2.11
  • MCHX $1.96
  • Analyst Decision
  • SAVA Hold
  • MCHX
  • Analyst Count
  • SAVA 1
  • MCHX 0
  • Target Price
  • SAVA $2.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • SAVA 517.9K
  • MCHX 20.0K
  • Earning Date
  • SAVA 11-06-2025
  • MCHX 10-30-2025
  • Dividend Yield
  • SAVA N/A
  • MCHX N/A
  • EPS Growth
  • SAVA N/A
  • MCHX N/A
  • EPS
  • SAVA N/A
  • MCHX N/A
  • Revenue
  • SAVA N/A
  • MCHX $47,534,000.00
  • Revenue This Year
  • SAVA N/A
  • MCHX N/A
  • Revenue Next Year
  • SAVA N/A
  • MCHX $7.56
  • P/E Ratio
  • SAVA N/A
  • MCHX N/A
  • Revenue Growth
  • SAVA N/A
  • MCHX N/A
  • 52 Week Low
  • SAVA $1.15
  • MCHX $1.26
  • 52 Week High
  • SAVA $33.98
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • SAVA 44.15
  • MCHX 46.15
  • Support Level
  • SAVA $2.12
  • MCHX $1.95
  • Resistance Level
  • SAVA $2.19
  • MCHX $2.03
  • Average True Range (ATR)
  • SAVA 0.10
  • MCHX 0.06
  • MACD
  • SAVA -0.02
  • MCHX 0.00
  • Stochastic Oscillator
  • SAVA 6.45
  • MCHX 20.59

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: